Reply from the Authors
We thank Dr. Busti for his interesting comments on our article [1] . The reason why we decided not to include atazanavir and tipranavir in our review is that they were either not available, or very recently released at the time we wrote this article. We thus thought that more clinical experience was needed before adding those drugs to such a review. However, Dr. Busti comments well complete our article, and we agree with his conclusions.
We totally agree that tenofovir and enfuvirtide have been misclassified in tables. This obviously results from an editing error.
Finally, we would not be as confident as Dr. Busti on the lack of interactions between immunosuppressive and tenofovir or enfuvirtide. Indeed, interactions through drug transporters in the kidney, the liver, and/or the intestine are frequent, and because tenofovir interactions with such transporters have been studied, some other pathways are still under investigation, as well as for enfuvirtide.
